malonic acid has been researched along with Huntington Disease in 18 studies
malonic acid : An alpha,omega-dicarboxylic acid in which the two carboxy groups are separated by a single methylene group.
dicarboxylic acid : Any carboxylic acid containing two carboxy groups.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malonic acid is a reversible inhibitor of mitochondrial enzyme complex-II, induces energy crisis and free radical generation." | 1.72 | Protective effect of 3-n-butylphthalide against intrastriatal injection of malonic acid-induced neurotoxicity and biochemical alteration in rats. ( Yuan, C; Zhao, Y; Zheng, L, 2022) |
| "Malonic acid (MA) is a reversible inhibitor of succinate dehydrogenase (SDH) which induces mitochondrial dysfunction followed by secondary excitotoxicity and apoptosis due to generation of reactive oxygen species." | 1.39 | Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. ( Kalonia, H; Kumar, A; Mishra, J; Sharma, N, 2013) |
| "Cystamine treatment of various genetic models of HD demonstrated protection against neurodegeneration and/or improvement in behavior." | 1.37 | Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. ( Leavitt, BR; Sivananthan, SN, 2011) |
| "Transgenic Huntington's disease (HD) mice, expressing exon 1 of the HD gene with an expanded CAG repeat, are totally resistant to striatal lesion induced by excessive NMDA receptor activation." | 1.31 | Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. ( Bates, GP; Brundin, P; Castilho, RF; Hansson, O; Korhonen, L; Lindholm, D, 2001) |
| "The gene defect in Huntington's disease (HD) may result in an impairment of energy metabolism." | 1.30 | Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. ( Beal, MF; Ferrante, RJ; Jenkins, BG; Kaddurah-Daouk, R; Matthews, RT; Rosen, BR; Yang, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, X | 1 |
| Zhang, H | 1 |
| Qu, T | 1 |
| Wang, Y | 1 |
| Zhong, Y | 1 |
| Yan, Y | 1 |
| Ji, X | 1 |
| Chi, T | 1 |
| Liu, P | 1 |
| Zou, L | 1 |
| Yuan, C | 1 |
| Zheng, L | 1 |
| Zhao, Y | 1 |
| Kumar, A | 2 |
| Sharma, N | 1 |
| Mishra, J | 1 |
| Kalonia, H | 2 |
| Sagredo, O | 2 |
| González, S | 1 |
| Aroyo, I | 1 |
| Pazos, MR | 1 |
| Benito, C | 1 |
| Lastres-Becker, I | 2 |
| Romero, JP | 1 |
| Tolón, RM | 1 |
| Mechoulam, R | 1 |
| Brouillet, E | 2 |
| Romero, J | 1 |
| Fernández-Ruiz, J | 4 |
| Kumar, P | 1 |
| Sivananthan, SN | 1 |
| Leavitt, BR | 1 |
| Valdeolivas, S | 1 |
| Satta, V | 1 |
| Pertwee, RG | 1 |
| Petersén, A | 1 |
| Puschban, Z | 1 |
| Lotharius, J | 1 |
| NicNiocaill, B | 1 |
| Wiekop, P | 1 |
| O'Connor, WT | 1 |
| Brundin, P | 2 |
| Bizat, N | 1 |
| Boyer, F | 1 |
| Hantraye, P | 1 |
| Alfinito, PD | 1 |
| Wang, SP | 1 |
| Manzino, L | 1 |
| Rijhsinghani, S | 1 |
| Zeevalk, GD | 1 |
| Sonsalla, PK | 1 |
| Murphy, RC | 1 |
| Messer, A | 1 |
| Klivenyi, P | 3 |
| Starkov, AA | 1 |
| Calingasan, NY | 1 |
| Gardian, G | 1 |
| Browne, SE | 1 |
| Yang, L | 2 |
| Bubber, P | 1 |
| Gibson, GE | 1 |
| Patel, MS | 1 |
| Beal, MF | 4 |
| de Lago, E | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Li, J | 1 |
| Calkins, MJ | 1 |
| Johnson, DA | 1 |
| Johnson, JA | 1 |
| Matthews, RT | 1 |
| Jenkins, BG | 1 |
| Ferrante, RJ | 3 |
| Rosen, BR | 1 |
| Kaddurah-Daouk, R | 1 |
| Andreassen, OA | 2 |
| Dedeoglu, A | 2 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Hughes, DB | 1 |
| Ona, VO | 1 |
| Friedlander, RM | 1 |
| Hansson, O | 1 |
| Castilho, RF | 1 |
| Korhonen, L | 1 |
| Lindholm, D | 1 |
| Bates, GP | 1 |
1 review available for malonic acid and Huntington Disease
| Article | Year |
|---|---|
Role of Nrf2-dependent ARE-driven antioxidant pathway in neuroprotection.
Topics: Animals; Antioxidants; Cell Death; Corpus Striatum; Disease Models, Animal; Electron Transport Compl | 2007 |
17 other studies available for malonic acid and Huntington Disease
| Article | Year |
|---|---|
Tolfenamic acid inhibits ROS-generating oxidase Nox1-regulated p53 activity in intrastriatal injection of malonic acid rats.
Topics: Animals; Apoptosis; Huntington Disease; Malonates; Mice; Oxidoreductases; Rats; Reactive Oxygen Spec | 2022 |
Protective effect of 3-n-butylphthalide against intrastriatal injection of malonic acid-induced neurotoxicity and biochemical alteration in rats.
Topics: Animals; beta Catenin; Huntington Disease; Nerve Growth Factors; Neuroprotective Agents; Neurotoxici | 2022 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
Topics: Animals; Arachidonic Acids; Camphanes; Cannabinoids; Cell Death; Central Nervous System Agents; Corp | 2009 |
Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats.
Topics: Animals; Body Weight; Disease Models, Animal; Drug Delivery Systems; Huntington Disease; Lipid Perox | 2010 |
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Topics: Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Eicosapentaenoic Acid; Huntington Disea | 2011 |
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Topics: Animals; Cannabidiol; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Combinations; Drug Ther | 2012 |
Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice.
Topics: Animals; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Fluorescent Dyes; Hu | 2002 |
Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
Topics: Animals; Cannabinoid Receptor Modulators; Cannabinoids; Corpus Striatum; Disease Models, Animal; Dro | 2003 |
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Str | 2003 |
A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.
Topics: Animals; Animals, Newborn; Biolistics; Cell Aggregation; Cell Count; Cell Death; Corpus Striatum; Cu | 2004 |
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Count; Cerebral Cortex; | 2004 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Antineoplastic Agents; Creatine; Creatinin | 1998 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant.
Topics: Animals; Brain; Caspase 1; Crosses, Genetic; Disease Models, Animal; Female; Huntington Disease; Mal | 2000 |
Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Topics: Aging; Amino Acid Chloromethyl Ketones; Animals; bcl-X Protein; Blood Glucose; Cell Death; Corpus St | 2001 |